Fasting glucose 109
Pro Research Analysisby 
Searched over 200M research papers
Understanding Fasting Glucose Levels of 109 mg/dL: Health Implications and Risks
Impaired Fasting Glucose (IFG) and Diagnostic Criteria
The American Diabetes Association (ADA) revised the threshold for diagnosing impaired fasting glucose (IFG) from 110 mg/dL to 100 mg/dL in 2003. This change aimed to identify individuals at risk of developing diabetes earlier and more effectively . Individuals with fasting plasma glucose (FPG) levels between 100 and 109 mg/dL are now considered to have IFG, a condition that indicates a higher risk of progressing to diabetes and associated complications .
Prevalence and Metabolic Risk Factors
Studies have shown that the new IFG criteria significantly increase the prevalence of individuals identified with IFG. In a Taiwanese population, 14.2% of participants were newly classified as having IFG with FPG levels between 100 and 109 mg/dL. These individuals exhibited higher body weight, body mass index (BMI), abdominal girth, blood pressure, and triglyceride levels compared to those with normal fasting glucose (NFG) levels. This suggests that even modest elevations in fasting glucose are associated with adverse metabolic profiles.
Risk of Developing Diabetes
Research indicates that individuals with FPG levels between 100 and 109 mg/dL have a significantly increased risk of developing diabetes. A study in Japan found that the hazard ratios for developing diabetes were 3.83 for those with FPG levels of 100-104 mg/dL and 7.87 for those with FPG levels of 105-109 mg/dL, compared to individuals with FPG levels below 85 mg/dL. This underscores the importance of monitoring and managing glucose levels even within this "pre-diabetic" range.
Insulin Resistance and Liver Function
Individuals with FPG levels between 100 and 109 mg/dL also show decreased insulin sensitivity and secretion. This is often accompanied by elevated liver enzymes, indicating a potential link between liver dysfunction and the progression of insulin resistance and type 2 diabetes. The homeostasis model assessment (HOMA) indices for insulin resistance (HOMA-IR) and beta-cell function (HOMA-%B) are significantly altered in this group, highlighting the metabolic disturbances associated with IFG.
Cardiovascular Risks
The cardiovascular risks associated with IFG are also notable. Individuals with FPG levels between 100 and 109 mg/dL have been found to have higher rates of endothelial dysfunction, a precursor to atherosclerosis and cardiovascular disease. Additionally, patients with stable angina and IFG in this range have a higher risk of adverse outcomes, such as death or myocardial infarction, following percutaneous coronary interventions.
Genetic Factors
Genetic studies have identified several loci associated with fasting glucose levels and insulin resistance. These genetic factors can influence glucose homeostasis and the risk of developing type 2 diabetes, further complicating the management of individuals with IFG.
Conclusion
Fasting glucose levels of 109 mg/dL, while not yet in the diabetic range, indicate a significant risk for developing diabetes and associated metabolic and cardiovascular complications. Early identification and management of individuals with IFG can help mitigate these risks and improve long-term health outcomes. Regular monitoring, lifestyle modifications, and possibly pharmacological interventions are essential strategies to prevent the progression to diabetes and its related health issues.
Sources and full results
Most relevant research papers on this topic